Philipp University Marburg, Department of Otolaryngology, Head and Neck Surgery, Deutschhausstrasse 3, 35037 Marburg, Germany.
Expert Opin Pharmacother. 2011 Feb;12(3):397-409. doi: 10.1517/14656566.2011.523698.
squamous-cell carcinoma of the head and neck (HNSCC) is one of the most common malignancies, the treatment of which constitutes a therapeutic challenge.
the purpose of this review is to provide an update on the pharmacotherapy for the treatment of HNSCC focusing mainly on molecular-targeted therapies. An overview of the different novel therapeutic agents that can selectively inhibit signaling pathways and receptors that are involved in the development and progression of cancer especially in HNSCC is presented.
the treatment of HNSCC is traditionally based on surgery and radiotherapy for early-stage HNSCC; however, chemotherapy is no longer used only for palliation, and individualized patient treatment assisted by molecular-targeted therapies represents a future therapeutic challenge.
头颈部鳞状细胞癌（HNSCC）是最常见的恶性肿瘤之一，其治疗构成了治疗挑战。
本文的目的是提供头颈部鳞状细胞癌治疗的药物治疗更新，主要侧重于分子靶向治疗。本文概述了不同的新型治疗药物，这些药物可以选择性地抑制参与癌症发展和进展的信号通路和受体，特别是在 HNSCC 中。
HNSCC 的传统治疗方法是早期 HNSCC 的手术和放疗；然而，化疗不再仅用于缓解症状，通过分子靶向治疗辅助的个体化患者治疗代表了未来的治疗挑战。
